479612-36-7

Usage

Uses

Used in Organic Synthesis:
6-Chloro-3-methyl-4-pyridinemethanol is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions, contributing to the creation of a wide range of organic compounds.
Used in Pharmaceutical Research:
In pharmaceutical research, 6-Chloro-3-methyl-4-pyridinemethanol is utilized as a key intermediate in the development of new drugs, aiding in the synthesis of pharmaceutically active molecules.
Used in Drug Development:
6-Chloro-3-methyl-4-pyridinemethanol is used in the development of drugs and pharmaceutical formulations due to its pharmacological properties, which can be harnessed to create new therapeutic agents.
Used in Chemical Industry:
6-Chloro-3-methyl-4-pyridinemethanol is used as a versatile building block in the chemical industry for the synthesis of various chemical products, including agrochemicals and specialty chemicals.

InChI:InChI=1/C7H8ClNO/c1-5-3-9-7(8)2-6(5)4-10/h2-3,10H,4H2,1H3

Upstream product

• 153034-94-7 2-Fluoro-4-iodo-5-methylpyridine 
• 1227570-92-4 4-iodo-5-methylpyridin-2(1H)-one 
• 787596-43-4 methyl 2-chloro-5-methylisonicotinate 
• 951030-56-1 2-chloro-5-methylisonicotinic acid 
• 58997-11-8 3-methylisonicotinic acid ethyl ester 
• 301666-87-5 3-Methyl-1-oxy-isonicotinic acid ethyl ester 

Relevant academic research and scientific papers

INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION

Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

PROCESS FOR PREPARING 1-ARYLSULFONYL-PYRROLIDINE-2-CARBOXAMIDE TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST COMPOUNDS AND CRYSTALLINE FORMS THEREOF

The invention relates generally to methods of preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide Transient Receptor Potential channel antagonist compounds of the following structure (I): (I) The invention further relates to solvate and co-crystal polymorphs of crystalline formula (I), and methods of preparation thereof.

Potent N-(1,3-Thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel

A series of N-(1,3-thiazol-2-yl)pyridin-2-amine KDR kinase inhibitors have been developed that possess optimal properties. Compounds have been discovered that exhibit excellent in vivo potency. The particular challenges of overcoming hERG binding activity and QTc increases in vivo in addition to achieving good pharmacokinetics have been acomplished by discovering a unique class of amine substituents. These compounds have a favorable kinase selectivity profile that can be accentuated with appropriate substitution.